Corcept Therapeutics Incorporated
CORTNASDAQHealthcare● Active
$73.33
+$0.71(+0.98%)
Market Cap$7.9B
P/E Ratio—
52W High$91
52W Low$28.66
Corcept Therapeutics Incorporated（CORT）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · CORT · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.10B | $0.14B | $0.11B | $0.10B | $0.11B |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.08B | $0.06B | $0.05B | $0.04B | $0.04B |
| Change in Working Capital | ($0.03B) | $0.05B | $0.01B | $0.01B | ($0.00B) |
| Net Cash from Operations | $0.14B | $0.20B | $0.13B | $0.12B | $0.17B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.32B) | ($0.59B) | ($0.33B) | ($0.36B) | ($0.31B) |
| Sales of Investments | $0.39B | $0.41B | $0.42B | $0.24B | $0.45B |
| Net Cash from Investing | $0.07B | ($0.18B) | $0.09B | ($0.11B) | $0.14B |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.25B) | ($0.02B) | ($0.15B) | $0.00B | ($0.30B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($0.22B) | ($0.03B) | ($0.15B) | ($0.02B) | ($0.30B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.14B | $0.20B | $0.13B | $0.12B | $0.17B |
| FCF Margin %(computed) | 18.62% | 29.02% | 26.31% | 29.84% | 45.75% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Corcept Therapeutics Incorporated
关于Corcept Therapeutics Incorporated（CORT）现金流量表
Corcept Therapeutics Incorporated 2025财年经营活动现金流$0.14B，自由现金流$0.14B（FCF利润率18.62%），资本支出($0.00B)。
常见问题
CORT · 4 问Corcept Therapeutics Incorporated 2025财年自由现金流$0.14B，同比down27.6%。
CORT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10